Value in Health · 2024 · 13 citations · 31 references
PharmacyPharmacoeconomicsCost-utility AnalysisHealth EconomicsHealthcare EconomicsEconomic EvaluationHealthcare Cost AnalysisModel-based Economic EvaluationOutcome ValuationPerspective In Economic EvaluationStrokeEndovascular Stroke TreatmentHospitalization CostsMethods Of Economic EvaluationMultiple ImputationOutcome MeasuresStroke Severity AssessmentStroke Severity ScalesStroke Severity Scoring
OBJECTIVES: Model-based health economic evaluations of ischemic stroke are in need of cost- and utility estimates related to relevant outcome measures. This study aims to describe societal cost- and utility estimates per modified Rankin Scale (mRS)-score at different time points within 2 years post stroke. METHODS: Included patients had a stroke between 3 months and 2.5 years ago. mRS and EQ-5D-5L were scored during a telephone interview. Based on the interview date, records were categorized into a time point: 3 months (3M; 3-6 months), 1 year (Y1; 6-18 months), or 2 years (Y2; 18-30 months). Patients completed a questionnaire on healthcare utilization and productivity losses in the previous 3 months. Initial stroke hospitalization costs were assessed. Mean costs and utilities per mRS and time point were derived with multiple imputation nested in bootstrapping. Cost at 3 months post stroke were estimated separately for endovascular treatment (EVT)-/non-EVT-patients. RESULTS: 1106 patients were included from 18 Dutch centers. At each time point, higher mRS-scores were associated with increasing average costs and decreasing average utility. Mean societal costs at 3M ranged from €11 943 (mRS 1, no EVT) to €55 957 (mRS 5, no EVT). For Y1, mean costs in the previous 3 months ranged from €885 (mRS 0) to €23 215 (mRS 5), and from €1655 (mRS 0) to €22 904 (mRS 5) for Y2. Mean utilities ranged from 0.07 to 0.96, depending on mRS and time point. CONCLUSIONS: The mRS-score is a major determinant of costs and utilities at different post-stroke time points. Our estimates may be used to inform future model-based health economic evaluations.
31
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Michael Herdman, Claire Gudex, Andrew Lloyd et al. · Quality of Life Research · 2011 · 10K citations · Full text
Interobserver agreement for the assessment of handicap in stroke patients.
John C. van Swieten, Peter J. Koudstaal, Marieke C. Visser et al. · Stroke · 1988 · 6.5K citations · Full text
Life Sciences, Neurology, Functional Movement Assessment +14
Heart Disease and Stroke Statistics—2021 Update
Salim S. Virani, Álvaro Alonso, Hugo J. Aparicio et al. · Circulation · 2021 · 5.8K citations · Full text